课题基金 / 基金详情

项目摘要

项目成果

LIVIA WAN的其他基金

相似基金

相关文献

中文摘要
翻译
为了降低静脉性感染的风险,需要无雌激素避孕
英文摘要
There is a demand for estrogen-free contraception in order to reduce the risk of venous thromboembolism (VTE), particularly for obese women. A new oral contraceptive agent consisting of a progesterone receptor modulator, which does not affect endogenous estrogen levels, has been developed. Ulipristal acetate (UPA) has been used in a single high dose for emergency contraception and has been used continuously for up to six months for treatment of uterine fibroids. Low dose continuous usage of oral UPA is anticipated to inhibit ovulation and provide an estrogen free, bleed free method of contraception.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE
CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - FEMALE SITES
CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE
CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE
海外基金